BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36945985)

  • 1. Assessment of HCV-RNA test results and access rates to antiviral treatment in patients with anti-HCV positivity-a 10-year analysis.
    Türkoğlu E; Parlak Z; Barut HŞ
    Turk J Med Sci; 2022 Dec; 52(6):1984-1990. PubMed ID: 36945985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
    Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
    World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands.
    Isfordink CJ; Smit C; Boyd A; de Regt MJA; Rijnders BJA; van Crevel R; Ackens RP; Reiss P; Arends JE; van der Valk M;
    AIDS; 2022 May; 36(6):773-783. PubMed ID: 34999607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
    van Tilborg M; Al Marzooqi SH; Wong WWL; Maan R; Vermehren J; Maasoumy B; Mazzulli T; Bolotin S; Garber G; Guerra F; Flud CR; Kowgier M; Janssen HL; de Knegt RJ; Pawlotsky JM; Cloherty GA; Duarte-Rojo A; Sarrazin C; Wedemeyer H; Feld JJ
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):856-864. PubMed ID: 30274834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
    Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
    J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital.
    Okushin K; Suzuki R; Tsutsumi T; Okamoto K; Ikeuchi K; Kado A; Minatsuki C; Minami-Kobayashi Y; Satoh N; Ikeda M; Harada S; Enooku K; Fujinaga H; Yotsuyanagi H; Koike K; Moriya K
    BMC Infect Dis; 2021 Apr; 21(1):399. PubMed ID: 33931015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of real life data of HCV from Turkey south region.
    Suntur BM; Kaya H; Eker HBŞ; Kara B; Bozok T; Unal N
    J Infect Dev Ctries; 2020 Apr; 14(4):380-386. PubMed ID: 32379715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Awareness of chronic hepatitis C in the Western Black Sea Region.
    Gok Sargin Z
    Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):7827-7832. PubMed ID: 36394730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HCV elimination in a Swiss opioid agonist therapy programme - a cohort study.
    Bregenzer A; Krismer C; Wendel S; Roser P; Fux CA
    Swiss Med Wkly; 2022 Dec; 152():40009. PubMed ID: 36509421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C microelimination among people living with HIV in Taiwan.
    Chen GJ; Ho SY; Su LH; Chang SY; Hsieh SM; Sheng WH; Liu WD; Huang YS; Lin KY; Chen YT; Su YC; Liu WC; Sun HY; Hung CC
    Emerg Microbes Infect; 2022 Dec; 11(1):1664-1671. PubMed ID: 35608049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns and trends of hepatitis C virus infection in Jordan: an observational study.
    Abu-Dayyeh I; Chemaitelly H; Ghunaim M; Hasan T; Abdelnour A; Abu-Raddad LJ
    Front Public Health; 2023; 11():1280427. PubMed ID: 38146470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria.
    Schwarz C; Bauer D; Dorn L; Jachs M; Hartl L; Chromy D; Weseslindtner L; Pfisterer N; Hennlich B; Stückler A; Strassl R; Voill-Glaninger A; Hübl W; Willheim M; Köhrer K; Jansen-Skoupy S; Tomez S; Krugluger W; Madl C; Schwarz M; Balcar L; Semmler G; Brinkmann L; Burghart L; Antonitsch L; Weidinger G; Riedl F; Laferl H; Kurteva V; Traugott M; Hind J; Wenisch C; Aburaia A; Sebesta C; Schmid D; Rothweiler S; Remetic J; Gschwantler M; Maieron A; Reiberger T
    Wien Klin Wochenschr; 2024 May; 136(9-10):278-288. PubMed ID: 37773541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaborative Referral Model for Hepatitis C Screening and Treatment in a Remote Mountainous Region of Taiwan during the COVID-19 Pandemic.
    Tai CM; Bair MJ; Chen TH; Tseng CH; Chen CC; Lam H; Yu ML
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort.
    Adland E; Jesuthasan G; Downs L; Wharton V; Wilde G; McNaughton AL; Collier J; Barnes E; Klenerman P; Andersson M; Jeffery K; Matthews PC
    BMC Infect Dis; 2018 Sep; 18(1):461. PubMed ID: 30217169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micro-elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policies.
    Mostafa A; Ebeid FSE; Khaled B; Ahmed RHM; El-Sayed MH
    Trop Med Int Health; 2020 Jul; 25(7):850-860. PubMed ID: 32306545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
    Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
    BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
    Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors.
    Bova S; Cameron A; Durand C; Katzianer J; LeGrand M; Boyer L; Glorioso J; Toman LP
    Am J Health Syst Pharm; 2022 Jan; 79(3):173-178. PubMed ID: 33987658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.